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Aims: To examine sleep complaints in patients with burning mouth 
syndrome (BMS) and the relationships between these disturbances, 
negative mood, and pain. Methods: Fifty BMS patients were com-
pared with an equal number of healthy controls matched for age, sex, 
and educational level. The Pittsburgh Sleep Quality Index (PSQI), 
the Epworth Sleepiness Scale (ESS), the Hamilton Rating Scales for 
Depression (HAM-D) and Anxiety (HAM-A) were administered. 
Descriptive statistics, including the Mann-Whitney U test and hier-
archical multiple linear regression analyses were used. Results: BMS 
patients had higher scores in all items of the PSQI and ESS than the 
healthy controls (P < .001). In the BMS patients, a depressed mood 
and anxiety correlated positively with sleep disturbances. The Pear-
son correlations were 0.68 for PSQI vs HAM-D (P < .001) and 0.63 
for PSQI vs HAM-A (P < .001). Conclusion: BMS patients reported 
a greater degree of sleep disorders, anxiety, and depression as com-
pared with controls. Sleep disorders could influence quality of life of 
BMS patients and could be a possible treatment target. J OROFAC 
PAIN 2013;27:XXX–XXX. doi: 10.11607/jop.1109
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Burning mouth syndrome (BMS) is an idiopathic, chronic pain condition that affects more than 1 million individuals in the United States alone,1 with an estimated prevalence ranging 
from 0.7% to 4.6%.2,3 It usually occurs in the fifth to seventh decade 
of life and is more common in females than in males, with a ratio of 
approximately 3:1.2,4
The International Association for the Study of Pain and the Inter-
national Headache Society define BMS as a “distinctive nosological 
entity,” including all forms of burning sensation in the mouth and 
complaints described as a stinging sensation or pain, in the absence 
of specific oral lesions and without alterations in blood tests and/or 
instrument findings.5
In almost all patients, BMS is characterized by sensory symptoms 
(burning, pain, a foreign-body sensation such as sand granularity, 
a decrease of salivation, and itching) involving mainly the tongue 
and lips, followed by the hard palate, alveolar ridges, cheeks, and 
floor of the mouth,6 which are not attributable to any organic pa-
thologies and are not supported by clinical findings. The discomfort 
may range from minimal to severe and may significantly affect the 
patient’s quality of life. It tends to persist for at least 4 to 6 months, 
to be constant and bilateral, and to be relieved with food consump-
tion. Other complaints may be associated with the burning, such 
as dysgeusia, hyposmia, and/or dysosmia, which supports its des-
ignation as a syndrome.7 The pathogenesis of BMS remains poorly 
understood, although both physiological and psychological factors 
have been hypothesized to be involved. Several studies have shown 
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an associated high prevalence of psychiatric symp-
toms and/or mental disorders in BMS patients, with 
good clinical responses to low-dose antidepressants 
and/or anti-anxiety medications.7,8 
Neurophysiological and imaging studies have 
suggested that a dysfunction of the nigrostriatal do-
paminergic pathway may play a role in the patho-
physiology of BMS,9,10 while other studies using 
functional magnetic resonance imaging (fMRI) 
have shown that patients with BMS have a specific 
qualitative and quantitative pattern of brain activa-
tion, leading to a net brain hypo-activity, suggesting 
that BMS patients may have a loss of function in 
the descending inhibitory serotonergic and noradr-
energic pathways causing, or at least contributing 
to, chronic pain.11
Sleep is vital to health and quality of life, whereas 
poor sleep is associated with adverse health conse-
quences12 and worsening medical or psychiatric dis-
eases (eg, chronic pain, dementia and depression).13
Insomnia is the most prevalent sleep problem and 
is characterized by a difficulty in falling or staying 
asleep, an early awakening or nonrestorative sleep 
in an individual who has adequate circumstances 
and opportunity for sleep.14 Impaired sleep gener-
ally has a negative effect on mood, pain severity ex-
perience, daytime functioning, and general quality 
of life.15–19 In particular, insomnia is often associated 
with somatic and pain symptoms.20 The association 
between sleep disturbances and pain is complex be-
cause sleep and pain are both associated with the 
activation of a number of central nervous system 
regions, with several studies suggesting that the su-
praspinal regions, the thalamocortical pathways, or 
the anterior cingulate cortex may be involved in the 
sleep-pain interaction.21,22 Although the mechanism 
has not been well studied, pain sensations could 
directly interrupt sleep. For example, chronic pain 
could cause a heightened arousal and vigilance, re-
ducing the quality and quantity of sleep, and chron-
ic pain and pain-related illness could cause cognitive 
and affective disturbances, which in turn cause in-
somnia.23,24 Consequently, it appears that pain could 
influence sleep through direct and indirect path-
ways, with a high prevalence of sleep-related distur-
bances in chronic pain patients typically reported in 
the 50% to 70% range.25 Moreover, insomnia is a 
common complaint in patients with pain symptoms 
related to their underlying medical disorders, such 
as rheumatoid arthritis and cancer.26 More recently, 
LeBlanc et al reported that a higher level of body 
pain was an important predictor for the incidence 
of insomnia,27,28 with a close and bidirectional rela-
tionship between insomnia and pain.29
Previous studies on associations between pain 
and negative effects suggest that a negative mood 
may increase the perception of pain; they report a 
clear relationship between sleep disorders and nega-
tive mood,30 with sleep problems being listed as a 
symptom of both major depression and anxiety dis-
orders in the Diagnostic and Statistical Manual of 
Mental Disorders–IV, Text Revision.31
The association of a negative mood, such as anxi-
ety or depression, with sleep disturbance could be 
related to common underlying pathophysiological 
mechanisms for sleep and mood regulation that 
make the individual vulnerable to both condi-
tions.30,32,33 In addition, a number of longitudinal 
studies indicate that poor sleep is a risk factor for 
major depression and anxiety.34
The relationship between pain, negative effects, 
and sleep is complex, and research has revealed 
contradictory data. Nicassio et al studied the rela-
tionship of pain and sleep with depression in 242 
patients suffering from rheumatoid arthritis. On 
cross-sectional analysis, the regression results indi-
cated that sleep disturbances and depression were 
closely associated. Depression was independent 
from pain when various demographic and func-
tional impairments were controlled in the model, 
whereas longitudinal analysis indicated that pain 
influenced later sleep but sleep difficulty was not 
associated with pain assessed 24 months later.35 In 
some studies, “poor sleepers” reported great pain 
but did not differ from “good sleepers” on measures 
of depression and anxiety. However, other studies 
reported that compared with “good sleepers,” “poor 
sleepers” had higher scores on measures of depres-
sion and anxiety, pain intensity, and greater physical 
disability.”13,36,37
Sleep disturbance in BMS patients is poorly docu-
mented, while mood disorders have been studied. 
The lack of research in this area may reflect the con-
ventional approach of considering sleep disturbance 
as a symptom of an underlying disorder rather than 
an independent clinical entity worthy of attention. 
The role that sleep disturbances play in BMS is un-
known. It was hypothesized that sleep disturbanc-
es affecting the quality of life could be considered 
worsening factors in patients with BMS. The pur-
pose of this study was to examine sleep complaints 
in patients with BMS and the relationships between 
these disturbances, negative mood, and pain. 
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Materials and Methods
Participants and Procedure
This was a case-control clinical study carried out 
at the Oral Medicine Unit, Federico II University of 
Naples. Sixty-six BMS cases and 57 healthy subjects 
were screened to participate between May 2010 and 
December 2010. Fifty BMS patients (response rate 
76%) and 50 healthy control subjects (response rate 
88%) were included in the trial in accordance with 
the inclusion/exclusion criteria, undergoing a simple 
randomization procedure with IBM SPSS software. 
Both groups were frequency-matched for sex, age, 
and educational level. All patients received written 
information and provided their written informed 
consent for the management of personal data before 
their participation. The study was approved by the 
local Ethical Committee. 
The inclusion criteria for BMS were (1) both 
sexes, aged 18 or older; (2) the presence of chronic 
pain in the oral mucosa in the absence of hard and 
soft tissue lesions of any kind; (3) pain lasting more 
than 6 months, continuous throughout the day, with 
no paroxysm and not following any unilateral nerve 
trajectory; and (4) the absence of any abnormali-
ties from the following laboratory investigations: 
salivary flow rates, laboratory tests, and tests for 
the detection of Candidiasis. The exclusion criteria 
encompassed patients presenting with organic con-
ditions that could be considered a causative factor, 
such as diabetes, anemia, thyroid disease, iposcialia-
related systemic disorders (eg, Sjogren’s syndrome), 
contact allergies, psychotic illness, organic brain 
syndrome, or neurological disease; subjects with 
signs of parafunctional habits; or patients regularly 
treated with anxiolytic, anti-depressant, anti-con-
vulsant, or psychotropic drugs. Even in the absence 
of mucosal lesions, a local effect of dental materials 
related to contact hypersensitivity was excluded by 
means of patch tests when the symptoms had start-
ed after any dental rehabilitation. A final diagnosis 
of BMS was established only after all other possible 
causes of the oral complaints had been ruled out.
The inclusion criteria for healthy subjects were (1) 
both sexes, aged 18 or older; (2) the absence of oral 
mucosal lesions; (3) no history of psychiatric disor-
der; and (4) consultation at the department exclu-
sively for dental disease (dental caries or periodontal 
disease). Conversely, the exclusion criteria encom-
passed (1) patients with unstable medical conditions 
or debilitating pathologies (eg, cancer, osteonecrosis, 
or autoimmune blistering disease) and (2) patients 
regularly treated with anxiolytic, anti-depressant, 
anti-convulsant, and/or psychotropic drugs.
Sociodemographic data, age, education, occupa-
tion, and marital status were recorded for both BMS 
patients and healthy subjects. At admission, each 
subject underwent a medical anamnesis (including 
history, clinical features, and treatment), a general 
medical examination, an intra- and extraoral ex-
amination, and laboratory tests (eg, full blood cell 
count, and serum levels of iron, ferritin, folate, vita-
min B12, and glucose).
Three oral medicine specialists were responsible 
for determining the eligibility of the BMS patients 
and of the healthy individuals as controls, and for 
collecting all the demographic and medical data 
from both groups. After screening, the BMS patients 
and controls were evaluated by a psychiatrist from 
the Department of Neuroscience of the same Uni-
versity Hospital.
Upon admission, the BMS patients and healthy 
controls were assessed in accordance with the fol-
lowing evaluation battery scales: the Pittsburgh 
Sleep Quality Index (PSQI) and the Epworth Sleepi-
ness Scale (ESS) for the assessment of sleep, the 
Hamilton Rating Scale for Depression (HAM-D) 
and the Hamilton Rating Scale for Anxiety (HAM-
A) for the evaluation of depression and anxiety, and 
the Numeric Rating Scale (NRS) for the measure-
ment of oral pain symptoms.
All these scales were reviewed for completeness 
before collection and were administered in their 
Italian versions.
Sleep Scales
The Pittsburgh Sleep Quality Index. The PSQI is 
considered an essential measure of sleep and in-
somnia symptoms in treatment research, and it is 
a recommended assessment tool for epidemiologi-
cal studies; it is a self-report questionnaire assess-
ing sleep quality and disturbances over a 1-month 
time interval, and is designed to be used in clinical 
populations.38 This instrument comprises 19 items, 
generating 7 “component” scores: subjective sleep 
quality, sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleep medica-
tion, and daytime dysfunction. Sleep pattern data 
(eg, bedtime, wake time, sleep onset latency, and 
sleep quantity) are also provided. Each item is scored 
from 0 to 3, with higher scores indicating poorer 
sleep or more frequent sleep problems. Items are 
combined to yield the 7 components (scores ranging 
from 0 to 3), and the sum of the scores for these 7 
components yields 1 global score ranging from 0 to 
21. Global scores above 5 distinguish poor sleep-
ers from good sleepers with a high sensitivity (90% 
to 99%) and specificity (84% to 87%).39 The psy-
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chometrics of the PSQI was subsequently evaluated 
by Carpenter and Andrykowsky40 in four different 
patient populations, and the results indicated that 
the PSQI had a good internal consistency and con-
struct validity. The PSQI has been translated into 
48 languages and has been used in a wide range of 
population-based and clinical studies.
The Epworth Sleepiness Scale. The ESS is a sim-
ple, self-administered questionnaire that provides a 
measurement of the subject’s general level of day-
time sleepiness; the ESS was first introduced by 
John in 1991.41 It does not require any instrumental 
evaluation, and is quick, inexpensive, flexible, and 
able to measure chronic sleepiness. The instrument 
comprises eight items assessing the propensity for 
sleep in eight common situations (eg, watching tele-
vision, or talking with someone). Subjects rate their 
likelihood of dozing in each situation on a scale of 
0 (would never doze) to 3 (a high chance of doz-
ing). The ESS score is the sum of the eight items. 
The ratings can be added together to form a total 
score of 24, with a cut-off value of > 10 indicating 
excessive daytime sleepiness. Several studies have 
used the ESS and it is a well-validated questionnaire. 
Psychometric analyses of the ESS support its inter-
nal consistency and unidimensionality.42 The ESS 
has been translated into 52 languages and has also 
been used in a wide range of population-based and 
clinical studies.
Depression and Anxiety Scales
The Hamilton Rating Scale for Depression. The 
HDRS (or HAM-D) has been the most frequently 
employed scale in clinical research.43,44 It is an inven-
tory employed to detect and identify the intensity 
or severity of the signs and symptoms of depres-
sion. The HDRS is the most widely used clinician-
administered depression assessment scale. It should 
be administered by a clinician experienced in work-
ing with psychiatric patients. Although the HAM-D 
form lists 21 items, the scoring is based on the first 
17. Eight items are scored on a 5-point scale, ranging 
from 0 = not present to 4 = severe. Nine are scored 
from 0 to 2. Scores can range from 0 to 54. A total 
score is computed to reflect the degree of symptom 
severity. A score > 10 indicates impairment. Scores 
between 10 and 17 indicate mild depression, scores 
between 18 and 24 indicate moderate depression, 
and scores over 24 indicate severe depression. Many 
of the psychometric properties of the HDRS are ad-
equate and consistently meet established criteria. 
The internal, inter-rater, and re-test reliability esti-
mates for the overall HDRS are mostly good, as are 
the internal reliability estimates at the item level.45
The Hamilton Rating Scale for Anxiety. The 
HAM-A is a rating scale developed to quantify the 
severity of anxiety symptomatology, often used in 
psychotropic drug evaluation.46,47 It consists of 14 
items, each defined by a series of symptoms. Each 
item is rated on a 5-point scale, ranging from 0 (not 
present) to 4 (severe), with a total score range of 0 
to 56. A score of below 17 indicates mild severity, 
scores in the 18 to 24 range indicate mild to moder-
ate severity, and from 25 to 30 indicate moderate 
to severe anxiety. It provides measures of overall 
anxiety, psychic anxiety (mental agitation and psy-
chological distress), and somatic anxiety (physical 
complaints related to anxiety). It is also used as an 
outcome measure when assessing the impact of anti-
anxiety medications, therapies, and treatments and 
is a standard measure of anxiety used in evaluations 
of psychotropic drugs. 
Oral Pain Scale
A numerical rating scale (NRS-11) was used for the 
evaluation of oral symptoms.48 This scale ranged 
from 0 to 10 (0 = no oral symptoms and 10 = the 
worst imaginable discomfort; therefore comprising 
11 integers including 0). The NRS is a well-validat-
ed instrument and is recommended for more com-
prehensive pain assessment. The literature shows 
that the NRS and the visual analog scale (VAS) are 
equally efficient for the evaluation of pain49; the 
NRS may be preferred for its ease of use, standard-
ized format, and better compliance. This scale was 
administered by interview undertaken by clinicians 
who asked the patients to assign a rating from 0 to 
10 in order to quantify the pain. The patients were 
then questioned as to their goals and expectations 
with respect to their pain rating as a measure of sat-
isfaction with the degree of analgesia.50
Statistical Analysis
Descriptive statistics, including means, standard 
deviations, medians, and interquartile range, were 
used to summarize all the variables. Considering 
the non-normality of the data analyzed, the Mann-
Whitney U test was employed to test the significance 
of the study parameters between the BMS patients 
and controls.
A series of hierarchical multiple linear regression 
analyses was performed to test the importance of 
disease-related and psychosocial factors to sleep 
quality after checking for demographic factors. 
Each hierarchical regression analysis computed 
whether the variance explained by the specific set 
contributed significantly to the total variance in 
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sleep quality after checking for the demographic set. 
A full model analysis was then computed with all 
the variables entered simultaneously into the model 
to determine the relative contributions of these vari-
ables to sleep quality.
Results
Table 1 summarizes the demographic and clinical 
parameters. There were 38 female patients (76%) 
and 12 male patients (24%).
PSQI Reliability
Table 2 shows the reliability analysis of PSQI in BMS 
patients. The Cronbach α measure 0.84 indicated a 
good overall reliability of the scale. All components 
presented an acceptable level of item-scale Pearson 
correlation. Item-scale correlation and Cronbach 
alpha index were used to verify the internal consist-
ency, item by item, and the global reliability of the 
PSQI in BMS patients and controls.
Table 1  Demographic and Clinical Characteristics of BMS Patients and Control Subjects
BMS patients Control subjects P
Demographic variables 
  Age (mean ± SD) 57.98 ± 8.1 53.2 ± 8.6 .832
  Years of education (mean ± SD) 8.4 ± 3.1 9.3 ± 2.9 .781
  Sex (female:male) 38:12 38:12 —
  Marital status (married:unmarried) 42:8 42:8 —
  Job full-time (yes:no) 11:39 11:39 —
Clinical parameters
  Sleep quality, PSQI (median; IQR) 9.0; 6–14 4.0; 3–5 < .001**
  Depression, HAM-D (median; IQR) 16.0; 10–24 5.0; 4–6 < .001**
  Anxiety, HAM-A (median; IQR) 17.5; 13–27 5.0; 4–7 < .001**
  Daytime sleepiness, ESS (median; IQR) 10.0; 7–12 3.0; 2–3 < .001**
  Pain severity, NRS (median; IQR) 8.5; 8–10 — —
IQR, interquartile range. The significance difference between medians was measured by Mann-Whitney U test. PSQI, Pittsburgh Sleep Quality In-
dex; HAM-D, HAM-A, Hamilton Rating Scale for Depression, Anxiety; ESS, Epworth Sleepiness Scale; NRS, numerical rating scale. *Significant .01 
< P ≤ .05, **Significant P ≤ .01. [Authors – here and Tables 3,4,5 footnotes: Is this wording necessary and the ** necessary in the Table since 
the actual p values are shown in the Tables?]
Table 2  Reliability Analysis of PSQI Scale in BMS Patients and Control Subjects
PSQI Components
Item-Scale ρ correlation 
BMS patients Control subjects
Subjective sleep quality 0.58 0.51
Sleep latency 0.76 0.32
Sleep duration 0.60 0.43
Habitual sleep efficiency 0.62 0.36
Sleep disturbances 0.54 0.03*
Use of sleep medications 0.31 0.61
Daytime dysfunction 0.63 0.17*
Cronbach alpha 0.84 0.65
*Poor correlation between a single item and the global scale (ρ < 0.3). 
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Sleep Quality
The global and component scores for the PSQI were 
significantly different between cases and controls 
(Tables 1 and 3). Patients with BMS had higher 
mean PSQI scores, indicating a poorer sleep qual-
ity for these patients compared to the healthy con-
trols. Forty patients (80%) were poor sleepers, with 
a PSQI global score of  > 5. 
Patients with Poor Quality of Sleep. Among BMS 
patients, the clinical parameters of good (PSQI < 5) 
and poor (PSQI > 5) sleepers were compared. De-
pression (P < .001), anxiety (P < .001), and daytime 
sleepiness (P < .001) were found to be significantly 
different between the two groups, while pain sever-
ity was not (P = .214) (Table 4).
Correlations of Sleep Quality. As shown in Ta-
ble 5, depression (HAM-D), anxiety (HAM-A), and 
daytime sleepiness (ESS) correlated positively with 
sleep disturbances [Authors – Do you mean “sleep 
quality” as shown in Table 5 heading?], while pain 
severity did not. In addition, the years of education 
correlated negatively with sleep disturbances.
Association with Sleep Quality. The results of the 
hierarchical multiple linear regression analyses pre-
dicting sleep quality are shown in Table 6. Model 
1 (the demographic model) tested the contribution 
of demographic variables to disturbed sleep. Model 
2 (the depression model) tested the contribution of 
depressed mood to poor sleep quality after control-
ling for the demographic variables. Model 3 (the 
anxiety model) tested the contribution of anxiety 
mood to poor sleep after checking for the demo-
graphic variables. Model 4 (the pain model) tested 
the contribution of pain severity after checking for 
the demographic variables. Model 5 is the standard 
regression analysis where all of the variables were 
entered simultaneously into the model to assess the 
relative contributions of these variables to sleep 
quality. This model takes into account the interre-
lations between the predictor variables as well as 
the effects of the predictor variables on the outcome 
variable (PSQI).
The first model testing the contributions of de-
mographic variables to sleep quality was not found 
to be statistically significant (R2 = 16.2%, P = .088). 
The addition of depression (model 2) and anxiety 
(model 3) resulted in a significant increase in the R2 
value (∆R2 = 45.3%, P < .001 for depression, ∆R2 
= 36.5%, P < .001 for anxiety) while the addition 
in model 4 [Authors – change OK?] of pain (NRS) 
Table 3  Comparison of Components of PSQI in BMS Patients and Control Subjects
PSQI components
BMS patients Control subjects
PMedian IQR Range Median IQR Range
Subjective sleep quality 1 1–2 0–3 1 1–1 0–2 .002**
Sleep latency 1 1–2 0–3 0 0–1 0–2 < .001**
Sleep duration 1 0–2 0–3 1 1–1 0–2 .199
Habitual sleep efficiency 1 0–2 0–3 1 0–1 0–3 .015*
Sleep disturbances 1 1–2 0–3 0 0–1 0–3 < .001**
Use of sleep medications 3 0–3 0–3 0 0–0 0–3 < .001**
Daytime dysfunction 1 1–2 0–3 0 0–1 0–4 < .001**
IQR, interquartile range. The significance difference between medians was measured by Mann-Whitney U test. *Significant .01 < P ≤ .05, **Signifi-
cant P ≤ .01. [Authors – see Table 1 query]
Table 4  Comparison Between Good and Poor Sleepers for BMS Patients
PSQI ≤ 5 (n = 23) PSQI > 5 (n = 27)
PMedian IQR Range Median IQR Range
Depression (HAM-D) 8.5 6–9 3–12 18 13–25 6–39 < .001**
Anxiety (HAM-A) 6.5 4–9 3–18 20 15.5–30 5–48 < .001**
Daytime sleepiness (ESS) 6.0 6–6 6–8 11 8–12 6–16 < .001**
Pain severity (NRS) 8.0 7–9 6–10 9 8–10 4–10 .214
PSQI, Pittsburgh Sleep Quality Index; IQR, interquartile range; HAM-D, HAM-A, Hamilton Rating Scale for Depression, Anxiety; ESS, Epworth 
Sleepiness Scale; NRS, numerical rating scale. The significance difference between medians was measured by Mann-Whitney U test. *Significant 
.01 < P ≤ .05, **Significant P ≤ .01. [Authors – see Table 1 query]
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did not contribute significantly to poor sleep qual-
ity. The final full model (the standard multiple re-
gression analysis) in which all of the variables were 
entered simultaneously could explain 62% of the 
variance in sleep quality.
The analysis of dependence reported in Table 5 
highlights a strong correlation between the PSQI 
and the ESS. This result is consistent with the simi-
lar nature of the two scales, and therefore the ESS 
can be considered as a proxy variable of the PSQI. 
For this reason, the ESS was excluded from the set 
of predictors considered in the hierarchical multiple 
linear regression analysis reported in Table 6.
Table 5  Correlation of Sleep Quality with Clinical Parameters and Demographic Characteristics for BMS Patients  
[Authors – change OK?]
Pearson coefficient P
Clinical parameters
  Depression (HAM-D) 0.68 < .001**
  Anxiety (HAM-A) 0.63 < .001**
  Daytime sleepiness (ESS) 0.85 < .001**
  Pan severity (NRS) 0.18 .213
Demographic characteristics
  Age 0.03 .858
  Years of education –0.32 .022*
Median; IQR
  Sex Female 9.0; 6–15 Male 8.5; 6–10.5 .368
  Marital status Married 9.0; 7–15 Unmarried 6.0; 5–9 .126
[Author: What does Median refer to regarding sex and marital age? Doesn’t seem to fit in this table showing correlation. Please explain.]
HAM-D, HAM-A, Hamilton Rating Scale for Depression, Anxiety; ESS, Epworth Sleepiness Scale; NRS, numerical rating scale; IQR, interquartile 
range. For the numerical variables, P values were obtained by Pearson correlation test. For the qualitative characteristics, P values were obtained 
by Mann-Whitney test. *Significant .01 < P ≤ .05, **Significant P ≤ .01. [Authors – see Table 1 query]
Table 6  Multiple Linear Regression Model Predicting Sleep Quality in BMS Patients
Model 1 Model 2 Model 3 Model 4 Model 5
Beta 
(SE) P
Beta 
(SE) P
Beta 
(SE) P
Beta 
(SE) P
Beta 
(SE) P
Predictors
Age –0.02 
(0.09)
.785 0.10 
(0.06)
.131 0.09 
(0.07)
.198 –0.01 
(0.09)
.944 0.01 
(0.06)
.144
Years of education –0.53 
(0.23)
.026* –0.48 
(0.16)
.004** –0.39 
(0.18)
.034* –0.49 
(0.24)
.043* –0.46 
(0.16)
.007**
Sex: Female 0.71 
(1.63)
.665 1.15 
(1.12)
.309 1.46 
(1.25)
.247 0.77 
(1.64)
.642 1.24 
(1.15)
.286
Marital status: Married –2.72 
(1.71)
.120 –0.57 
(1.22)
.641 –0.64 
(1.35)
.637 –2.58 
(1.74)
.145 –0.49 
(1.24)
.693
Depression (HAM-D) 0.39 <.001** 0.32 
(0.11)
.005**
Anxiety (HAM-A) 0.29 
(0.05)
<.001** 0.07 
(0.09)
.452
Pain severity (NRS) 0.37 
(0.47)
.440 –0.13 
(0.36)
.720
R2 (%) 16.2 .088 61.5 <.001** 52.7 <.001** 17.3 .125 62.0 <.001**
R2 change (%) 45.3 <.001** 36.5 <.001** 1.1 .440 45.8 <.001**
SE, standard errors of beta estimates. HAM-D, HAM-A, Hamilton Rating Scale for Depression, Anxiety; ESS, Epworth Sleepiness Scale; NRS, nu-
merical rating scale. P values were obtained by hypothesis test on regression coefficients. + Suggestive of significance .05 < P ≤ .10, *Significant 
.01 < P ≤ .05, **Significant P ≤ .01. [Authors: There are no + significance values noted in table. [Authors – see Table 1 query]
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Discussion
Previous studies have demonstrated that sleep disor-
ders occur in up to 27% of the primary-care popu-
lation and more frequently (ranging from 51% to 
75%) in the elderly and in patients with advanced 
medical illness.51,52 In clinical populations, the prev-
alence of sleep disturbance has been estimated to 
be about 51% of patients who experience chronic 
low back pain, 75% of those with fibromyalgia, and 
70% of those with rheumatoid arthritis.53
In the present study, the prevalence of poor sleep 
in patients with BMS was 80%, with the global 
PSQI and all of the component scores significantly 
higher in BMS patients compared to controls. This 
clearly depicts the poorer sleep quality of BMS pa-
tients when compared to healthy subjects. While in 
previous studies it has been reported that sleep dis-
orders can increase pain, which in turn may cause 
sleep disorders,54–57 the measurement of pain (NRS) 
in this study was similar in both groups, good and 
poor sleepers. Forty patients (poor sleepers) had a 
clinically significant depressed mood and anxiety. 
None of these patients was taking antidepressants. 
This could be due to the probable underestimation 
of depression and anxiety in diseases such as BMS.
Previous studies have commonly reported a high-
er presence of negative mood in both chronic pain 
populations and individuals with sleep problems.32 
However, previous findings of the interrelationships 
between sleep, pain, and negative mood have been 
inconsistent in the existing literature.58,59 Some stud-
ies have reported higher levels of depression and/
or anxiety among chronic pain patients with sleep 
disturbances; other studies have not found these 
relationships.13,37,58–60
In the present study, the association between 
depression, anxiety, daytime sleepiness, and sleep 
quality in BMS patients, which was evident and sig-
nificant on bivariate analysis, remained significant 
in standard multiple regression analyses. Therefore, 
depression and anxiety could be important risk fac-
tors of sleep disturbance in BMS patients.
It is possible that high levels of negative mood 
may increase or perpetuate the impact of sleep 
disturbances in BMS patients, possibly through 
mechanisms of increased physiological or cognitive 
arousal or dysregulated diurnal patterns (eg, de-
creased physical and social activities during the day, 
increased time in bed combined with high levels of 
daytime sleepiness). These symptoms and behaviors 
are common in the clinical pictures of both depres-
sion and anxiety. Additionally, it is not difficult to 
see how a negative mood and sleep disturbances can 
each act to increase the other, leading to a cycle that 
perpetuates itself if there is no intervening action to 
disrupt it.61,62
In previous studies, the association between pain 
symptoms and sleep disturbances has been demon-
strated based on epidemiological data,37 with con-
troversial data on the worsening effect of poor sleep 
on chronic pain complaints.18,19,63 Morin et al also 
reported that chronic pain preceded or coincided 
with a complaint of poor sleep in approximately 
90% of patients in an outpatient pain clinic.59 In 
that study, pain was considered the causal factor of 
sleep disturbances and generally improved with pain 
management. There is a lack of data in the literature 
on the relationship between sleep quality and pain 
intensity; however, even if the correlation between 
sleep disturbances and the intensity of pain symp-
toms needs to be addressed, it is possible to consider 
that a prolonged period of pain and a long history 
of unsuccessful treatment can, in time, worsen sleep 
quality. In a previous study that analyzed anxiety, 
depression, and pain in BMS patients, the authors 
demonstrated that pain increases along with anxi-
ety and depression, and not with illness duration.64 
Although pain, sleep disturbance, and psychological 
distress are frequently observed in various chronic 
pain conditions, it is difficult to determine which of 
these conditions begins first. There is controversy as 
to whether psychogenic factors are primary or sec-
ondary events, because chronic pain conditions may 
affect and alter the subject’s psychological profile.65,66
Treatment of BMS includes the administration 
of low doses of benzodiazepines, including clonaz-
epam.67,68 The mechanism of action of these drugs in 
BMS is unknown. However, it is known that these 
medications have an effect on sleep and have also 
been used in the treatment of insomnia.69 It is possi-
ble that this effect on promoting sleep may partially 
explain the mechanism of action of these drugs in 
BMS.69–71 The results from the present study suggest 
a new direction for etiological and interventional 
research in BMS, but larger prospective studies are 
needed to add to our knowledge of the causative 
role of sleep in BMS. In addition, a suitable therapy 
to improve sleep quality could be evaluated as an 
intervention for BMS.72
Study Limitations
There are several limitations to the current study. 
First, because of the small size of the sample, com-
posed largely of women (76%), and because this 
study was performed in a single tertiary care center, 
the results may not be generalizable. Second, the 
pain rating scales in the BMS patients suffer from a 
ceiling effect, with many pain ratings near or at the 
Adamo et al
Journal of Orofacial Pain 9
top of the scale. For this reason, pain rating scales 
could be inadequate to assess pain intensity and its 
correlation with sleep quality. Third, only the inten-
sity and not the type and pattern of pain has been 
considered. The type of pain may be equally impor-
tant in the evaluation of patients, and may be an im-
portant determinant of sleep quality. And last, this 
was a case-control study, unsuitable to evaluate the 
prospective relationships between pain, sleep, and 
psychological disorders.
Conclusions
This study has confirmed the comorbidity of sleep 
disturbance and psychological distress in a sample 
of BMS patients. In contrast, pain intensity did not 
correlate with sleep quality. The study has demon-
strated that sleep disturbance is a common problem 
among BMS patients and has highlighted the impor-
tance of assessing sleep variables in clinical evalu-
ation and, possibly, in treatment. Future studies 
should try to gain an understanding of the patho-
physiological relationships between these sleep 
disturbances, anxiety and depression, and their bio-
logical background.
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